Abecma

FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Flag link:
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
Flag link:
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
Fierce Pharma
Bristol Myers Squibb
ASH 2022
Abecma
clinical trials
Multiple Myeloma
Flag link:
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Flag link:
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
BioPharma Dive
Bristol Myers Squibb
2seventy bio
Abecma
CAR-T
Multiple Myeloma
Flag link:
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Fierce Pharma
oncology
cancer
IQVIA
Bristol Myers Squibb
Abecma
Amgen
Lumakras
Flag link:
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Fierce Pharma
Bristol Myers Squibb
CAR-T
Breyanzi
Abecma
Flag link:
As Abecma sales take off, Bristol Myers and 2seventy scrap a follow-up CAR-T
As Abecma sales take off, Bristol Myers and 2seventy scrap a follow-up CAR-T
Endpoints
Bristol Myers Squibb
2seventy bio
Abecma
bb21217
CAR-T
Flag link:
Bristol Myers sees automation, virtual reality on the horizon for pair of new CAR-T manufacturing plants
Bristol Myers sees automation, virtual reality on the horizon for pair of new CAR-T manufacturing plants
Fierce Pharma
Bristol Myers Squibb
CAR-T
drug manufacturing
Breyanzi
Abecma
Flag link:
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Fierce Pharma
Bristol Myers Squibb
Bluebird Bio
CAR-T
JNJ
Legend Biotech
Abecma
Flag link:
FDA approves first CAR-T cell therapy for multiple myeloma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA
Flag link: